A Phase 3 interventional study of methotrexate and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 13 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 11 that started in 2012, is one of 47 in phase 3, and was the 61st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 89th largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 124th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in patients with mild to moderate rheumatoid arthritis, with an inadequate response to methotrexate. Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks plus oral methotrexate 15-25 mg weekly for 12 weeks. Patients with a good/moderate EULAR response will then be randomized to receive either RoActemra/Actemra plus methotrexate or RoActemra/Actemra plus placebo for the following 12 weeks. Anticipated time on study treatment is 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
Drug: methotrexate · Drug: placebo · Drug: tocilizumab [RoActemra/Actemra]
15-25 mg orally weekly, Weeks 1-12
15-25 mg orally weekly, Weeks 13-24
methotrexate placebo orally weekly, Weeks 13-24
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks, 24 weeks
Change From Week 12 (Randomization) to Week 24 in DAS28
The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\] + \[0.014 \* GH in mm visual analogue assessment (VAS)\]. A negative change from randomization indicated improvement.
Time frame: Weeks 12 and 24
Percentage of Participants With DAS28 Remission at Week 24
The DAS28 is a combined index for measuring disease activity in RA. The index includes SJC and TJC, both scored 0-28 (higher scores indicate higher disease activity, as well as APR determined as ESR, and GH, both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 = 0.56 \* √ of TJC + 0.28 \* √ of SJC + 0.70 \* ln ESR mm/hr + 0.014 \* GH in mm VAS. DAS28 \< 2.6 = remission.
Time frame: Week 24
vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24
The CDAI is a combined index for measuring disease activity in RA. CDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), as well as patient global assessment (PGA) and evaluator global assessment (EGA) of disease activity, both scored 0 to 10 centimeter (cm) as assessed by VAS. CDAI was calculated according to the following formula: CDAI = SJC + TJC + PGA + EGA. CDAI \< 2.8 = remission.
Time frame: Week 24
Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24
The SDAI is a combined index for measuring disease activity in RA. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), PGA and EGA of disease activity, both scored 0 to 10 cm as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal \< 1 mg/dL. CDAI was calculated according to the following formula: SDAI = TJC + SJC + PGA + EGA + CRP. SDAI \< 3.3 = remission.
Time frame: Week 24
Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24
The RADAI-5 is a combined index for measuring disease activity in RA. RADAI-5 is comprised of the following 5 questions: how active was your arthritis the last 6 months? (0 = completely inactive to 10 = extremely active); how active is your arthritis today with respect to joint tenderness and swelling? (0 = completely inactive to 10 = extremely active); how severe is your arthritis pain today? (0 = no pain to 10 = unbearable pain); how would you describe your general health today? (0 = very good to 10 = very bad); and did you experience joint (hand) stiffness on awakening yesterday morning? If yes, how long did this stiffness last? (0 = no stiffness to 10 = stiffness the whole day). RADAI was calculated according to the following formula: \[question (Q) 1 + Q2 + Q3 + Q4 + Q5\]/5. RADAI-5 from 0-1.4 = remission.
Time frame: Week 24
Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
HAQ-DI scores were obtained by scoring participants' responses to a 20-item questionnaire. HAQ-DQ evaluated 8 domains of health: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities from a range of 0 (without any difficulty) to 3 (unable to do). The sum of scores was divided by the number of domains for a total score of 0 (best) to 3 (worst). A negative change from randomization indicated improvement.
Time frame: Weeks 12 and 24
Change From Week 12 (Randomization) to Week 24 in Short Form-36 Health Survey (SF-36) Score
SF-36 scores were obtained by scoring participants' responses to a 36-item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores. A negative change from randomization indicated improvement.
Time frame: Weeks 12 and 24
Change From Week 12 (Randomization) to Week 24 in Visual Analog Scales (VAS) Scores
VAS scores were obtained by scoring participants' disease activity as assessed on a 0-100 millimeter (mm) horizontal visual scale. The left-hand extreme of the line = 0 mm (no disease activity = symptom-free and no arthritis symptoms), and the right-hand extreme of the line = 100 mm (maximum disease activity). A negative change from randomization indicated improvement.
Time frame: Weeks 12 and 24
Participant Satisfaction With Treatment as Assessed by Treatment Satisfaction Questionnaire for Medication (TSQM) Score
TSQM scores were obtained by scoring participants' responses to a 14-item questionnaire. TSQM evaluated 4 aspects of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction from a range of 0 to 100 percent (%), with 100% being the best possible result.
Time frame: Week 24
| Milestone | All Participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|---|
| Started | 77 | 0 | 0 |
| Completed | 65 | 0 | 0 |
| Not completed | 12 | 0 | 0 |
| Withdrew: Physician decision | 7 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: No eular response | 4 | 0 | 0 |
| Milestone | All Participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|---|
| Started | 0 | 32 | 33 |
| Completed | 0 | 30 | 32 |
| Not completed | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Screening failure | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 |
The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis (RA). The index includes swollen joint counts (SJC) and tender joint counts (TJC), both scored 0-28 (higher scores indicate higher disease activity), as well as acute phase response (APR) determined as erythrocyte sedimentation rate (ESR), and general health (GH), both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 equals (=) \[0.56 multiplied by (\*) the square root (√) of TJC\] plus (+) \[0.28 \* √ of SJC\] + (0.70 \* the natural logarithm (ln) ESR in millimeters per hour (mm/h)\] + \[0.014 \* GH in mm visual analogue assessment (VAS)\]. A negative change from randomization indicated improvement.
| score on a scale | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Change From Week 12 (Randomization) to Week 24 in DAS28 | 0.17 ± 0.83 | -0.16 ± 1.13 |
The DAS28 is a combined index for measuring disease activity in RA. The index includes SJC and TJC, both scored 0-28 (higher scores indicate higher disease activity, as well as APR determined as ESR, and GH, both scored 1-100 (higher scores indicate higher disease activity). DAS28 was calculated according to the following formula: DAS28 = 0.56 \* √ of TJC + 0.28 \* √ of SJC + 0.70 \* ln ESR mm/hr + 0.014 \* GH in mm VAS. DAS28 \< 2.6 = remission.
| percentage of participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Percentage of Participants With DAS28 Remission at Week 24 | 81.25 | 87.50 |
The CDAI is a combined index for measuring disease activity in RA. CDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), as well as patient global assessment (PGA) and evaluator global assessment (EGA) of disease activity, both scored 0 to 10 centimeter (cm) as assessed by VAS. CDAI was calculated according to the following formula: CDAI = SJC + TJC + PGA + EGA. CDAI \< 2.8 = remission.
| percentage of participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| vPercentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 24 | 34.38 | 53.13 |
The SDAI is a combined index for measuring disease activity in RA. SDAI is the sum of TJC and SJC, both scored 0-28 (higher scores indicate higher disease activity), PGA and EGA of disease activity, both scored 0 to 10 cm as assessed by VAS, and C-reactive protein level (CRP) in milligrams per deciliter (mg/dL) where normal \< 1 mg/dL. CDAI was calculated according to the following formula: SDAI = TJC + SJC + PGA + EGA + CRP. SDAI \< 3.3 = remission.
| percentage of participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 24 | 40.63 | 53.13 |
The RADAI-5 is a combined index for measuring disease activity in RA. RADAI-5 is comprised of the following 5 questions: how active was your arthritis the last 6 months? (0 = completely inactive to 10 = extremely active); how active is your arthritis today with respect to joint tenderness and swelling? (0 = completely inactive to 10 = extremely active); how severe is your arthritis pain today? (0 = no pain to 10 = unbearable pain); how would you describe your general health today? (0 = very good to 10 = very bad); and did you experience joint (hand) stiffness on awakening yesterday morning? If yes, how long did this stiffness last? (0 = no stiffness to 10 = stiffness the whole day). RADAI was calculated according to the following formula: \[question (Q) 1 + Q2 + Q3 + Q4 + Q5\]/5. RADAI-5 from 0-1.4 = remission.
| percentage of participants | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Percentage of Participants With Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5) Remission at Week 24 | 32.26 | 54.55 |
HAQ-DI scores were obtained by scoring participants' responses to a 20-item questionnaire. HAQ-DQ evaluated 8 domains of health: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities from a range of 0 (without any difficulty) to 3 (unable to do). The sum of scores was divided by the number of domains for a total score of 0 (best) to 3 (worst). A negative change from randomization indicated improvement.
| score on a scale | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Change From Week 12 (Randomization) to Week 24 in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score | 0.04 ± 0.28 | -0.06 ± 0.40 |
SF-36 scores were obtained by scoring participants' responses to a 36-item questionnaire. SF-36 evaluated 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health from a range of 1 (better) to 5 (worst). The score for each section was an average of the individual question scores, which were scaled 0-100 (100=highest level of functioning). These 8 aspects were summarized as physical and mental component scores. A negative change from randomization indicated improvement.
| score on a scale | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Physical standardized value | 0.89 ± 10.48 | 0.75 ± 10.08 |
| Mental standardized value | -5.41 ± 9.24 | -1.69 ± 9.20 |
VAS scores were obtained by scoring participants' disease activity as assessed on a 0-100 millimeter (mm) horizontal visual scale. The left-hand extreme of the line = 0 mm (no disease activity = symptom-free and no arthritis symptoms), and the right-hand extreme of the line = 100 mm (maximum disease activity). A negative change from randomization indicated improvement.
| score on a scale | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Fatigue | 1.91 ± 17.16 | -1.88 ± 17.49 |
| Pain | 1.09 ± 18.48 | -2.88 ± 22.04 |
TSQM scores were obtained by scoring participants' responses to a 14-item questionnaire. TSQM evaluated 4 aspects of treatment satisfaction: effectiveness, side effects, convenience, and global satisfaction from a range of 0 to 100 percent (%), with 100% being the best possible result.
| score on a scale | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Effectiveness | 72.41 ± 34.85 | 82.49 ± 24.14 |
| Side-effects | 94.15 ± 19.16 | 94.89 ± 14.70 |
| Convenience | 85.48 ± 21.97 | 86.03 ± 15.60 |
| Global satisfaction | 86.64 ± 21.09 | 86.36 ± 13.53 |
Collected over Adverse events (AEs) were collected from Weeks 12-24.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: TCZ + MTX | — | 2/32 (6.3%) | 14/32 (43.8%) |
| Group B: TCZ + Placebo | — | 5/33 (15.2%) | 12/33 (36.4%) |
| Event | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/32 | 0/33 |
| Cerebrovascular accidentNervous system disorders | 1/32 | 0/33 |
| Joint effusionMusculoskeletal and connective tissue disorders | 0/32 | 1/33 |
| Urinary tract infectionInfections and infestations | 0/32 | 1/33 |
| LacerationInjury, poisoning and procedural complications | 0/32 | 1/33 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/32 | 1/33 |
| GastritisGastrointestinal disorders | 0/32 | 1/33 |
| Event | Group A: TCZ + MTX | Group B: TCZ + Placebo |
|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 5/32 | 2/33 |
| NasopharyngitisInfections and infestations | 5/32 | 1/33 |
| NauseaGastrointestinal disorders | 3/32 | 5/33 |
| Oral herpesInfections and infestations | 1/32 | 5/33 |
| Alanine aminotransferase increasedInvestigations | 4/32 | 5/33 |
| Aspartate aminotransferase increasedInvestigations | 3/32 | 4/33 |
Intent to treat (ITT) population: all randomized participants who received at least 1 dose of study treatment.
| Age, Continuous(years) | Group A: TCZ + MTX | Group B: TCZ + Placebo | Total |
|---|---|---|---|
| Mean | 57.78 ± 11.88 | 57.15 ± 10.83 | 57.46 ± 11.28 |
| Sex: Female, Male(Participants) | Group A: TCZ + MTX | Group B: TCZ + Placebo | Total |
|---|---|---|---|
| Female | 26 | 25 | 51 |
| Male | 6 | 8 | 14 |
The record gives a start of Feb 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Tocilizumab